Rapport Therapeutics CEO sells 8,210 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay reported open-market sales of 8,210 shares of common stock on July 14, 2026, in two transactions at weighted-average prices of $40.57 and $39.72, executed under Rule 10b5-1 trading plans adopted on March 27, 2026. Following these sales, he holds 539,817 shares directly. Additional shares are held in two irrevocable trusts (20,729 and 81,729 shares), for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Insider Trade Summary 10b5-1
Net Seller: 8,210 shares
Net Sell
4 txns
Insider
Ceesay Abraham
Role
Chief Executive Officer
Sold
8,210 shs ($328K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 5,481 | $39.7217 | $218K |
| Sale | Common Stock F1, F3 | 2,729 | $40.5724 | $111K |
| holding | Common Stock F4 | -- | -- | -- |
| holding | Common Stock F5 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 539,817 shares (Direct);
Common Stock — 81,729 shares (Indirect, By Ceesay Family Irrevocable Trust);
Common Stock — 20,729 shares (Indirect, By Dorothy Ceesay Irrevocable Trust)
Footnotes (5)
- F1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.36 to $40.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.37 to $40.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F4. Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- F5. Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Key Figures
Total shares sold: 8,210 shares
First transaction size and price: 2,729 shares at $40.5724
Second transaction size and price: 5,481 shares at $39.7217
+5 more
8 metrics
Total shares sold
8,210 shares
Aggregate common shares sold by CEO on July 14, 2026
First transaction size and price
2,729 shares at $40.5724
Open-market sale of common stock on July 14, 2026
Second transaction size and price
5,481 shares at $39.7217
Open-market sale of common stock on July 14, 2026
Direct holdings after sale
542,546 shares
Common stock held directly by CEO following transactions
Dorothy Ceesay Irrevocable Trust holdings
20,729 shares
Indirect holdings via Dorothy Ceesay Irrevocable Trust
Ceesay Family Irrevocable Trust holdings
81,729 shares
Indirect holdings via Ceesay Family Irrevocable Trust
Price range first weighted average
$39.36–$40.35
Range of prices for trades included in first weighted-average sale
Price range second weighted average
$40.37–$40.73
Range of prices for trades included in second weighted-average sale
Key Terms
Rule 10b5-1 trading plans, weighted average price, irrevocable trust, beneficial ownership
4 terms
Rule 10b5-1 trading plans regulatory
"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans"
Rule 10b5-1 trading plans are written, pre-arranged instructions that allow company insiders (such as executives or directors) to automatically buy or sell their company's stock at specified times or under set conditions, like a standing instruction or automated thermostat for trades. They matter to investors because these plans provide a legal defense against insider‑trading accusations and create predictable insider trading patterns that can help signal whether sales are routine portfolio management or potentially meaningful to the company’s outlook.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
irrevocable trust financial
"Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Rapport Therapeutics (RAPP) report for CEO Abraham Ceesay?
Abraham Ceesay reported selling 8,210 shares of Rapport Therapeutics common stock on July 14, 2026 in two open-market transactions, while retaining a substantial direct stake plus additional shares held in related irrevocable trusts.
What is the role of irrevocable trusts in the Rapport Therapeutics (RAPP) Form 4?
Two irrevocable trusts hold 20,729 and 81,729 shares of Rapport Therapeutics common stock. The CEO reports these as indirect holdings and expressly disclaims beneficial ownership for Section 16 purposes except to the extent of any pecuniary interest.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates